Reproductive variables, fertility drugs and epithelial ovarian tumor risk

CME Journal of Gynecologic Oncology

Volumn 9, Issue 3 PART 4, 2004, Pages 245-252

  Gadducci, Angiolo ^a   Gargini, Antonio ^a   Palla, Elisabetta ^a   Genazzani, Andrea Riccardo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Borderline ovarian tumor; Clomiphene; Fertility drug; Gonadotropin; Hormones; Infertility; Ovarian carcinoma

Indexed keywords

ANDROGEN RECEPTOR; CLOMIFENE CITRATE; ESTROGEN RECEPTOR; FOLLITROPIN; GONADOTROPIN; LUTEINIZING HORMONE; MITOGEN ACTIVATED PROTEIN KINASE; ORAL CONTRACEPTIVE AGENT; PROTEIN BCL 2; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

CANCER INCIDENCE; CANCER INVASION; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HORMONAL CARCINOGENESIS; HUMAN; HYSTERECTOMY; INFERTILITY THERAPY; MALIGNANT TRANSFORMATION; NULLIPARA; ORAL CONTRACEPTION; OVARY CANCER; OVARY FOLLICLE CELL; OVARY TUMOR; OVULATION INDUCTION; PRECANCER; REVIEW; RISK ASSESSMENT; SALPINGOOOPHORECTOMY; TUMOR PROMOTION; UPREGULATION;

EID: 35748974502     PISSN: 12199087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (127)

1. Riman T, Persson I, Nilsson S. Hormonal aspects of epithelial ovarian cancer:review of epidemiological evidence. Clin Endocrinol 1998;49:695-707.
2. Partridge EE, Barnes MN. Epithelial ovarian cancer:prevention, diagnosis, and treatment. CA Cancer J Clin 1999;49:297-320.
3. Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology and prognostic factors. Semin Surg Oncol 2000;19:3-10.
4. Ozols RF. Update on the management of ovarian cancer Cancer J 2002;8(Suppl 11):22-30.
5. Luce TL, Dow KH, Holcomb L. Early diagnosis key to epithelial ovarian cancer detection. Nurse Pract 2003;28:41-47.
6. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
7. du Bois A, Luck HJ, Meier W, Mobus V, Costa S, Richter B, et al. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynakologische Onkologie Ovarian cancer Study Group. Semin Oncol 1997;24(Suppl 15):15-52.
8. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92:699-708.
9. Neijt JP, Engelholm SA, Tuxen MK, Sorensen PG, Hansen M, Sessa C, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000;18:3084-3092.
10. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194-3200.
11. Gertig DM, Hunter DJ, Cramer DW, Colditz GA, Speizer FE, Willett WC, et al. Prospective study of talc use and ovarian cancer. J Natl Cancer Inst 2000;92:249-252.
12. Green A, Purdie D, Bain C, Siskind V, Russell P, Quinn M, et al. Tubal sterilisation, hysterectomy and decreased risk of ovarian cancer. Survey of Women's Health Study Group. Int J Cancer 1997;71:948-951.
13. Piek JM, van Diest PJ, Zweemer RP, Kenemans P, Verheijen RH. Tubal ligation and risk of ovarian cancer. Lancet 2001;358:844.
14. Ylikorkala O. Tubal ligation reduces the risk of ovarian cancer. Acta Obstet Gynecol Scand 2001;80:875-877.
15. Gjorgov AN. Tubal ligation and risk of ovarian cancer. Lancet 2001;358:843-844.
16. Huncharek M, Geschwind JF, Kupelnick B. Perineal application of cosmetic talc and risk of invasive epithelial ovarian cancer: a meta-analysis of 11.933 subjects from sixteen observational studies. Anticancer Res 2003;23:1955-1960.
17. Brinton LA, Melton LJ 3rd, Malkasian GD Jr, Bond A, Hoover R. Cancer risk after evaluation for infertility. Am J Epidemiol 1989;129:712-722.
18. Gwinn ML, Lee NC, Rhodes PH, Layde PM, Rubin GL. Pregnancy, breast feeding, and oral contraceptives and the risk of epithelial ovarian cancer. J Clin Epidemiol 1990;43:559-568.
19. Negri E, Franceschi S, Tzonou A, Booth M, La Vecchia C, Parazzini F, et al. Pooled analysis of 3 European case-control studies: I. Reproductive factors and risk of epithelial ovarian cancer. Int J Cancer 1991;49:50-56.
20. Franceschi S, La Vecchia C, Booth M, Tzonou A, Negri E, Parazzini F, et al. Pooled analysis of 3 European case-control studies of ovarian cancer: II. Age at menarche and at menopause. Int J Cancer 1991;49:57-60.
21. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian cancer Group. Am J Epidemiol 1992;136:1212-1220.
22. Rossing MA, Daling, JR, Weiss NS, Moore DE, Self SG. Ovarian tumors in a cohort of infertile women. N Engl J Med 1994;331:771-776.
23. Adami HO, Hsieh CC, Lambe M, Trichopoulos D, Leon D, Persson I, et al. Parity, age at first childbirth, and risk of ovarian cancer. Lancet 1994;344:1250-1254.
24. Mosgaard BJ, Lidegaard O, Kjaer SK, Schou G, Andersen AN. Infertility, fertility drugs, and invasive ovarian cancer:a case-control study. Fertil Steril 1997;67:1005-1012.
25. Gnagy S, Ming EE, Devesa SS, Hartge P, Whittemore AS. Declining ovarian cancer rates in U.S. women in relation to parity and oral contraceptive use. Epidemiology 2000;11:102-105.
26. Siskind V, Green A, Bain C, Purdie D. Beyond ovulation:oral contraceptives and epithelial ovarian cancer. Epidemiology 2000;11:106-110.
27. Chiaffarino F, Pelucchi C, Parazzini F, Negri E, Franceschi S, Talamini R, et al. Reproductive and hormonal factors and ovarian cancer. Ann Oncol 2001;12:337-341.
28. Titus-Ernstoff L, Perez K, Cramer DW, Harlow BL, Baron JA, Greenberg ER. Menstrual and reproductive factors in relation to ovarian cancer risk. Br J Cancer 2001;84:714-721.
29. Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, et al. Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study. Am J Epidemiol 2002;156:363-373.
30. Zhang M, Lee AH, Binns CW. Reproductive and dietary risk factors for epithelial ovarian cancer in China. Gynecol Oncol 2004;92:320-326.
31. Persson I, Yuen J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy - long-term follow-up of a Swedish cohort. Int J Cancer 1996;67:327-332.
32. Hempling RE, Wong C, Piver MS, Natarajan N, Mettlin CJ. Hormone replacement therapy as a risk factor for epithelial ovarian cancer: results of a case-control study. Obstet Gynecol 1997;89:1012-1016.
33. Garg PP, Kerlikowske K, Subak L, Grady D. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol 1998;92:472-479.
34. Purdie DM, Bain CJ, Siskind V, Russell P, Hacker NF, Ward BG, et al. Hormone replacement therapy and risk of epithelial ovarian cancer. Br J Cancer 1999;81:559-563.
35. Coughlin SS, Giustozzi A, Smith SJ, Lee NC. A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. J Clin Epidemiol 2000;53:367-375.
36. Genazzani AR, Gadducci A, Gambacciani M. International Menopause Society Expert Workshop Controversial issues in climacteric medicine II. Hormone Replacement Therapy Cancer Matur 2001;40:117-130.
37. Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 2001;285:1460-1465.
38. Sit AS, Modugno F, Weissfeld JL, Berga SL, Ness RB. Hormone replacement therapy formulations and risk of epithelial ovarian carcinoma. Gynecol Oncol 2002;86:118-123.
39. Harlow BL, Weiss NS, Roth GS, Chu J, Daling JR. Case-control study of borderline ovarian tumors: reproductive history and exposure to exogenous female hormones. Cancer Res 1988;48:5849-5852.
40. Becher H, Schmidt S, Chang-Claude J. Reproductive factors and familial predisposition for breast cancer by age 50 years. A case-control-family study for assessing main effects and possible gene-environment interaction. Int J Epidemiol 2003;32:38-48.
41. Rosenblatt KA, Thomas DB. Lactation and the risk of epithelial ovarian cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Epidemiol 1993;22:192-197.
42. Siskind V, Green A, Bain C, Purdie D. Breastfeeding, menopause, and epithelial ovarian cancer. Epidemiology 1997;8:188-191.
43. Tung KH, Goodman MT, Wu AH, McDuffie K, Wilkens LR, Kolonel LN, et al. Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study. Am J Epidemiol 2003;158:629-638.
44. Modugno F, Ness RB, Wheeler JE. Reproductive risk factors for epithelial ovarian cancer according to histologic type and invasiveness. Ann Epidemiol 2001;11:568-574.
45. Campi R, Frydenberg M, Basso O, Ebbesen P, Olsen J. Having children with different men and subsequent cancer risk. A nationwide study in Denmark. Br J Cancer 2004;90:1374-1377.
46. Rodriguez C, Tatham LM, Calle EE, Thun MJ, Jacobs EJ, Heath CW Jr. Infertility and risk of fatal ovarian cancer in a prospective cohort of US women. Cancer Caus Control 1998;9:645-651.
47. Bosetti C, Negri E, Trichopoulos D, Franceschi S, Beral V, Tzonou A, et al. Long-term effects of oral contraceptives on ovarian cancer risk. Int J Cancer 2002;102:262-265.
48. Deligeoroglou E, Michailidis E, Creatsas G. Oral contraceptives and reproductive system Cancer Ann NY Acad Sci 2003;997:199-208.
49. Sanderson M, Williams MA, Weiss NS, Hendrix NW, Chauhan SP. Oral contraceptives and epithelial ovarian cancer. Does dose matter? J Reprod Med 2000;45:720-726.
50. Royar J, Becher H, Chang-Claude J. Low-dose oral contraceptives: protective effect on ovarian cancer risk. Int J Cancer 2001;95:370-374.
51. Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst 2002;94:32-38.
52. Narod SA, Risch H, Moslehi R, Dorum A, Neuhausen S, Olsson H, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998;339:424-428.
53. Harris R, Whittemore AS, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992;136:1204-1211.
54. Mosgaard BJ, Lidegaard O, Kjaer SK, Schou G, Andersen AN. Ovarian stimulation and borderline ovarian tumors: a case-control study. Fertil Steril 1998;70:1049-1055.
55. Lacey JV Jr, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P, et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 2002;288:334-341.
56. Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, et al. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 2002;94:497-504.
57. Cardillo MR, Petrangeli E, Aliotta N, Salvatori L, Ravenna L, Chang C, et al. Androgen receptors in ovarian tumors: correlation with oestrogen and progesterone receptors in an immunohistochemical and semiquantitative image analysis study. J Exp Clin Cancer Res 1998;17:231-237.
58. Lau KM, Mok SC, Ho SM. Expression of human estrogen receptor-alpha and - beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci U.S.A. 1999;96:5722-5727.
59. Akahira J, Inoue T, Suzuki T, Ito K, Konno R, Sato S, et al. Progesterone receptor isoforms A and B in human epithelial ovarian carcinoma: immunohistochemical and RT-PCR studies. Br J Cancer 2000;83:1488-1494.
60. Parrott JA, Doraiswamy V, Kim G, Mosher R, Skinner MK. Expression and actions of both the follicle stimulating hormone receptor and the luteinizing hormone receptor in normal ovarian surface epithelium and ovarian cancer. Mol Cell Endocrinol 2001;172:213-222.
61. Lindgren P, Backstrom T, Mahlck CG, Ridderheim M, Cajander S. Steroid receptors and hormones in relation to cell proliferation and apoptosis in poorly differentiated epithelial ovarian tumors. Int J Oncol 2001;19:31-38.
62. Fujimura M, Hidaka T, Kataoka K, Yamakawa Y, Akada S, Teranishi A, et al. Absence of estrogen receptor-alpha expression in human ovarian clear cell adenocarcinoma compared with ovarian serous, endometrioid, and mucinous adenocarcinoma. Am J Surg Pathol 2001;25:667-672.
63. Syed V, Ulinski G, Mok SC, Yiu GK, Ho SM. Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res 2001;61:6768-6776.
64. Li AJ, Baldwin RL, Karlan BY. Estrogen and progesterone receptor subtype expression in normal and malignant ovarian epithelial cell cultures. Am J Obstet Gynecol 2003;189:22-27.
65. Li AJ, Baldwin RL, Karlan BY. Short androgen receptor allele length is a poor prognostic factor in epithelial ovarian carcinoma. Clin Cancer Res 2003;9:3667-3673.
66. Modugno F. Ovarian cancer and polymorphisms in the androgen and progesterone receptor genes: A HuGE review. Am J Epidemiol 2004;159:319-335.
67. Choi KC, Kang SK, Tai CJ, Auersperg N, Leung PC. Follicle-stimulating hormone activates mitogen-activated protein kinase in preneoplastic and neoplastic ovarian surface epithelial cells. J Clin Endocrinol Metab 2002;87:2245-2253.
68. Stewart SL, Querec TD, Gruver BN, O'Hare B, Babb JS, Patriotis C. Gonadotropin and steroid hormones stimulate proliferation of the rat ovarian surface epithelium. J Cell Physiol 2004;198:119-224.
69. Choi KC, Kang SK, Tai CJ, Auersperg N, Leung PC. Estradiol up-regulates antiapoptotic Bcl-2 messenger ribonucleic acid and protein in tumorigenic ovarian surface epithelium cells. Endocrinology 2001;142:2351-2360.
70. Rodriguez GC, Walmer DK, Cline M, Krigman H, Lessey BA, Whitaker RS, et al. Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis? J Soc Gynecol Investig 1998;5:271-276.
71. Rodriguez GC, Nagarsheth NP, Lee KL, Bentley RC, Walmer DK, Cline M, et al. Progestin-induced apoptosis in the Macaque ovarian epithelium:differential regulation of transforming growth factor-beta. J Natl Cancer Inst 2002;94:50-60.
72. Syed V, Ho SM. Progesterone-induced apoptosis in immortalized normal and malignant human ovarian surface epithelial cells involves enhanced expression of FasL. Oncogene 2003;22:6883-6890.
73. Evangelou A, Jindal SK, Brown TJ, Letarte M. Down-regulation of transforming growth factor beta receptors by androgen in ovarian cancer cells. Cancer Res 2000;60:929-935.
74. Cramer DW, Hutchison B, Welch WR, Scully RE, Ryan KJ. Determinants of ovarian cancer risk. I. Reproductive experiences and family history. J Natl Cancer Inst 1983;71:711-716.
75. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998;90:1774-1786.
76. Konishi I, Kuroda H, Mandai M. Review: gonadotropins and development of ovarian cancer. Oncology 1999;57(Suppl 2):45-48.
77. Atlas M, Menczer J. Massive hyperstimulation and borderline carcinoma of the ovary. A possible association. Acta Obstet Gynecol Scand 1982;61:261-1633.
78. Bamford PN, Steele SJ. Uterine and ovarian carcinoma in a patient receiving gonadotrophin therapy. Case report. Br J Obstet Gynaecol 1982;89:962-964.
79. Carter ME, Joyce DN. Ovarian carcinoma in a patient hyperstimulated by gonadotropin therapy for in vitro fertilization: a case report. J In Vitro Fert Embryo Transf 1987;4:126-128.
80. Goldberg GL, Runowicz CD. Ovarian carcinoma of low malignant potential, infertility, and induction of ovulation - is there a link? Am J Obstet Gynecol 1992;166:853-854.
81. Nijman HW, Burger CW, Baak JPA, Schats R, Vermorken JB, Kenemans P. Borderline malignancy of the ovary and controlled hyperstimulation, a report of 2 cases. Eur J Cancer 1992;28A:1971-1973.
82. Shushan A, Brzezinski A, Schenker JG. Hormonal treatments and genital cancer: an update. In: Frontiers in gynecologic and obstetric investigation. Genazzani AR, Petraglia F, Genazzani AD, eds. The Parthenon Publishing Group, New York, USA, 1993:163-184.
83. Hull ME, Kriner M, Schneider E, Maiman M. Ovarian cancer after successful ovulation induction:a case report. J Reprod Med 1996;41:52-54.
84. Grimbizis G, Tarlatzis BC, Bontis J, Miliaras D, Lagos S, Pournaropoulos F, et al. Two cases of ovarian tumours in women who had undergone multiple ovarian stimulation attempts. Hum Reprod 1995;10:520-523.
85. Anderson SM, Dimitrievich E. Ovulation induction for infertility is it safe or not? S D J Med 1996;49:419-421.
86. Kobayashi F, Monma C, Nanbu K, Konishi I, Sagawa N, Mori T. Rapid growth of an ovarian clear cell carcinoma expressing LH/hCG receptor arising from endometriosis during early pregnancy. Gynecol Oncol 1996;62:309-313.
87. Salle B, de Saint Hilaire P, Devouassoux M, Gaucherand P, Rudigoz C. Another two cases of ovarian tumours in women who had undergone multiple ovulation induction cycles. Hum Reprod 1997;12:1732-1735.
88. Unkila-Kallio L, Leminen A, Tiitnen A, Lehtovirta P, Wahlstrom T, Ylikorkala O. Malignant tumors of the ovary or the breast in association with infertility: a report of thirteen cases. Acta Obstet Gynecol Scand 1997;76:177-181.
89. Abboud J, Attieh E, Atallah D, Kessrouani A, Chaoul G. Three cases of ovarian cancer after ovulation induction for infertility. Contracept Fertil Sex 1997;25:64-65.
90. Adewole IF, Babarinsa IA, Thomas JO, Ajayi AB. Ovarian cancer associated with ovulation induction: a case report. Afr J Med Med Sci 1997;26:203-204.
91. Ghourab S. Synchronous endometrioid carcinoma of the ovary and endometrium associated with ovulation induction. Saudi Med J 2001;22:914-916.
92. Goshen R, Weissman A, Shoham Z. Epithelial ovarian cancer, infertility and induction of ovulation:possible pathogenesis and updated concepts. Baillieres Clin Obstet Gynaecol 1998;12:581-591.
93. Fishel S, Jackson P. Follicular stimulation for high tech pregnancies:are we playing it safe? BMJ 1989;299:309-311.
94. Nieto JJ, Crow J, Sundaresan M, Constantinovici N, Perrett CW, MacLean AB, et al. Ovarian epithelial dysplasia in relation to ovulation induction and nulliparity. Gynecol Oncol 2001;82:344-349.
95. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992;136:1184-1203.
96. Shushan A, Paltiel O, Iscovich J, Elchalal U, Peretz T, Schenker JG. Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertil Steril 1996;65:13-18.
97. Kashyap S, Moher D, Fung MF, Rosenwaks Z. Assisted reproductive technology and the incidence of ovarian cancer: a meta-analysis. Obstet Gynecol 2004;103:785-794.
98. Modan B, Ron E, Lerner-Geva L, Blumstein T, Menczer J, Rabinovici J, et al. Cancer incidence in a cohort of infertile women. Am J Epidemiol 1998;147:1038-1042.
99. Venn A, Watson L, Bruinsma F, Giles G, Healy D. Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet 1999;354:1586-1590.
100. Potashnik G, Lerner-Geva L, Genkin L, Chetrit A, Lunenfeld E, Porath A. Fertility drugs and the risk of breast and ovarian cancers:results of a long-term follow-up study. Fertil Steril 1999;71:853-859.
101. Parazzini F, Pelucchi C, Negri E, Franceschi S, Talamini R, Montella M, et al. Use of fertility drugs and risk of ovarian cancer. Hum Reprod 2001;16:1372-1375.
102. Dor J, Lerner-Geva L, Rabinovici J, Chetrit A, Levran D, Lunenfeld B, et al. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertil Steril 2002;77:324-327.
103. Doyle P, Maconochie N, Beral V, Swerdlow AJ, Tan SL. Cancer incidence following treatment for infertility at a clinic in the UK. Hum Reprod 2002;17:2209-2213.
104. Ness RB, Cramer DW, Goodman MT, Kjaer SK, Mallin K, Mosgaard BJ, et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol 2002;155:217-224.
105. Bandera CA, Cramer DW, Friedman AJ, Sheets EE. Fertility therapy in the setting of a history of invasive epithelial ovarian cancer. Gynecol Oncol 1995;58:116-119.
106. Baykal C, Al A, Demirol A, Bozdag G, Ayhan A. Twin pregnancy after ICSI in a patient with ovarian cancer complicated with maternal hepatitis-C: a case report. Eur J Obstet Gynecol Reprod Biol 2002;102:96-97.
107. Steinkampf MP, Dharia SP, Hammond K. Assisted reproduction in patients with early-stage ovarian malignancies. Fertil Steril 2003;80:1510-1512.
108. Parazzini F, Negri E, La Vecchia C, Moroni S, Polatti A, Chiaffarino F, et al. Treatment for fertility and risk of ovarian tumors of borderline malignancy. Gynecol Oncol 1998;68:226-228.
109. Shushan A, Paltiel O, Schenker JG. Induction of ovulation and borderline ovarian cancer - the hormonal connection? Eur J Obstet Gynecol Reprod Biol 1999;85:71-74.
110. Abu-Jawdeh GM, Jacobs TW, Niloff J, Cannistra SA. Estrogen receptor expression is a common feature of ovarian borderline tumors. Gynecol Oncol 1996;60:301-307.
111. Iscovich J, Shushan A, Schenker JG , Paltiel O. The incidence of borderline ovarian tumors in Israel: a population-based study. Cancer 1998;82 :147-151.
112. Modan B, Gak E, Sade-Bruchim RB, Hirsh-Yechezkel G, Theodor L, Lubin F, et al. High frequency of BRCA1 185delAG mutation in ovarian cancer in Israel. National Israel Study of Ovarian Cancer. JAMA 1996;276:1823-1825.
113. Rodriguez G. New insights regarding pharmacologic approaches for ovarian cancer prevention. Hematol Oncol Clin North Am 2003;17:1007-1020.
114. Purdie DM, Bain CJ, Siskind V, Webb PM, Green AC. Ovulation and risk of epithelial ovarian cancer. Int J Cancer 2003;104:228-232.
115. Schildkraut JM, Bastos E, Berchuck A. Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer. J Natl Cancer Inst 1997;89:932-938.
116. Webb PM, Green A, Cummings MC, Purdie DM, Walsh MD, Chenevix-Trench G Relationship between number of ovulatory cycles and accumulation of mutant p53 in epithelial ovarian cancer. J Natl Cancer Inst 1998;90:1729-1734.
117. Whiteman DC, Siskind V, Purdie DM, Green AC. Timing of pregnancy and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2003;12:42-46.
118. Bristow RE, Karlan BY. Ovulation induction, infertility, and ovarian cancer risk. Fertil Steril 1996;66:499-507.
119. Burmeister L, Healy DL. Ovarian cancer in infertility patients. Ann Med 1998;30:525-528.
120. Duckitt K, Templeton AA. Cancer in women with infertility. Curr Opin Obstet Gynecol 1998;10:199-203.
121. Shoham Z. Epidemiology, etiology, and fertility drugs in ovarian epithelial carcinoma: where are we today? Fertil Steril 1994;62:433-448.
122. Bristow RE, Karlan BY. The risk of ovarian cancer after treatment for infertility. Curr Opin Obstet Gynecol 1996;8:32-37.
123. Artini PG, Fasciani A, Cela V, Battaglia C, de Micheroux AA, D'Ambrogio G, et al. Fertility drugs and ovarian cancer. Gynecol Endocrinol 1997;11:59-68.
124. Rossing MA, Daling JR. Complexity of surveillance for cancer risk associated with in-vitro fertilisation. Lancet 1999;354:1573-1574.
125. Beltsos AN, Odem RR. Ovulation induction and ovarian malignancy. Semin Reprod Endocrinol 1996;14:367-374.
126. Rosen B, Irvine J, Ritvo P, Shapiro H, Stewart D, Reynolds K, et al. The feasibility of assessing women's perceptions of the risks and benefits of fertility drug therapy in relation to ovarian cancer risk. Fertil Steril 1997;68:90-94.
127. Klip H, Burger CW, Kenemans P, van Leeuwen FE. Cancer risk associated with subfertility and ovulation induction: a review. Cancer Causes Control 2000;11:319-344.